<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0030">The keynote address, Hepatitis B virus: an ancient curse and the modern blessing for its cure, delivered by Jake Liang (National Institutes of Health, Maryland, USA) reviewed most aspects of HBV molecular biology with particular emphasis on current and novel viral targets that may help advancing more effective therapies. The HBV treatment with licensed therapies currently includes six nucleoside/nucleotide analogues and two types of interferon whose limitations include: 
 <list list-type="simple" id="JVEv5-list-0003">
  <list-item id="JVEv5-li-0010">
   <label>•</label>
   <p id="JVEv5-para-0031">Rare loss of HBsAg-positive status in HBV carriers;</p>
  </list-item>
  <list-item id="JVEv5-li-0011">
   <label>•</label>
   <p id="JVEv5-para-0032">Treatment achieves only partial reversal of hepatic fibrosis and inflammation;</p>
  </list-item>
  <list-item id="JVEv5-li-0012">
   <label>•</label>
   <p id="JVEv5-para-0033">Decreased but not eliminated risk of hepatocellular carcinoma; and</p>
  </list-item>
  <list-item id="JVEv5-li-0013">
   <label>•</label>
   <p id="JVEv5-para-0034">High cost and adverse effects of prolonged therapy.</p>
  </list-item>
 </list>
</p>
